Annual sales fell from KRW 94.2 billion in 2022 to KRW 88.5 billion in 2023 (down 6.1% year on year), KRW 30.9 billion in 2024 (down 65.0%) and KRW 7.89 billion in 2025 (down 74.5%). Sales declined for three consecutive years from 2023 to 2025, and the 2025 figure is less than one-tenth of the 2022 level.
Operating losses were KRW 9.52 billion in 2022, KRW 9.36 billion in 2023, KRW 12.6 billion in 2024 and KRW 1.6 billion in 2025, a deficit in each of the four years, with operating margins of -10.1%, -10.6%, -40.8% and -20.2%.
The 2024 operating loss was the largest of the four years, while the 2025 loss narrowed even though sales fell 74.5% in the same year.
By segment, a Korea Ratings assessment dated April 2024 showed the genome analysis services operating loss at about KRW 7.4 billion and the medical device distribution loss at about KRW 3.3 billion in 2022, and about KRW 5.5 billion and KRW 3.2 billion in 2023.
The same assessment linked the 2021 shift of the medical device distribution business into losses to lower prices for diagnostic kits. Operating cash flow moved from -KRW 10.9 billion in 2022 and -KRW 14 billion in 2023 to KRW 6.69 billion in 2024 and KRW 3.5 billion in 2025, turning positive.
Net profit attributable to controlling shareholders was a loss of KRW 29.9 billion in 2022, a loss of KRW 33 billion in 2023 and a loss of KRW 95.2 billion in 2024, before turning to KRW 28.2 billion in 2025.
On a quarterly basis, sales moved from KRW 1.79 billion in the third quarter of 2025 to KRW 1.26 billion in the third quarter of 2026, down 29.5% year on year. The first-quarter 2026 operating loss of KRW 1.3 billion was the largest among the last five quarters.
Net profit attributable to controlling shareholders of KRW 20.2 billion in the fourth quarter of 2025 and KRW 24.7 billion in the first quarter of 2026 were far larger than the operating losses of KRW 362 million and KRW 1.3 billion in those quarters, which points to a large effect from non-operating items.
The sum over the latest four quarters is KRW 42.8 billion, but the second and third quarters of 2026 returned to losses of KRW 730 million and KRW 1.42 billion.